

1fw

Practitioner's Docket No. 701039-053543

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In application of: Mark Puder; Arin K. Greene; Judah Folkman
 Application No.: 10/767,870 Group No.: To be assigned
 Filed: January 29, 2004 Examiner: To be assigned
 For: PREVENTION OF SURGICAL ADHESIONS USING SELECTIVE COX-2 INHIBITORS

CERTIFICATE OF MAILING/TRANSMISSION (37 C.F.R. § 1.8(a) and 1.10)

I hereby certify that this correspondence:

1. Certificate of Mail (1 pg.);
2. Transmittal Form (1 pg.);
3. Information Disclosure Statement with Form 1449 (6 pp.);
4. References AA, BA, CA-CI and CK-CV;
5. Change of Attorney's Address (1 pg.); and
6. Return Receipt Postcard.

is on the date shown below being:

MAILING

deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to the MAIL STOP AMENDMENT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22202

Date: May 20, 2004


FACSIMILE

transmitted by facsimile to the U.S. Patent and Trademark Office.



Signature
Linda M. Ginsberg
 (type or print name of person certifying)

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.


**TRANSMITTAL
FORM**

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission

Application Number	10/767,870
Filing Date	January 29, 2004
First Named Inventor	Mark Puder
Art Unit	To be assigned
Examiner Name	To be assigned
Attorney Docket Number	701039-53543

ENCLOSURES (Check all that apply)

<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance Communication to Group
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment/Reply	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input checked="" type="checkbox"/> Power of Attorney, Revocation	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Change of Correspondence Address	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	Certificate of Mail; References AA, BA, CA-CI and CK-CV ; and Return Receipt Postcard
<input checked="" type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Request for Refund	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Response to Missing Parts/ Incomplete Application		
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53		
Remarks		
The Commissioner is hereby authorized to charge any additional fees associated with this communication to Deposit Account No. 50-0850.		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual name	David S. Resnick (34,235) Nixon Peabody LLP, 100 Summer Street, Boston, MA 02110
Signature	
Date	May 20, 2004

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below. Washington, DC 20231 on this date:

Typed or printed name	Linda M. Ginsberg
Signature	
Date	May 20, 2004

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



Practitioner's Docket No. 701039-053543

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Mark Puder; Arin K. Greene; Judah Folkman
Application No.: 10/767,870 Group No.: To be assigned
Filed: January 29, 2004 Examiner: To be assigned
For: PREVENTION OF SURGICAL ADHESIONS USING SELECTIVE COX-2 INHIBITORS

MAIL STOP AMENDMENT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

CERTIFICATE OF MAILING

I hereby certify that this correspondence is, on the date shown below, being: deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to the MAIL STOP AMENDMENT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Date: May 24, 2004

Sir:

INFORMATION DISCLOSURE STATEMENT

In accordance with the provisions of 37 C.F.R. §§1.56 and 1.97, Applicants herewith submit the publications and/or patents shown on the attached Form 08B, for consideration by the Examiner in connection with the examination of the above-identified patent application.

REMARKS

In accordance with the provisions of 37 C.F.R. §1.97, this statement is being filed:

- X (1) within three (3) months of the Filing Date or **before the mailing date of the First Office Action** on the merits; or
- (2) within three months of the mailing date of the PCT International Search Report; or
- (3) after the period defined in (1) but before the mailing date of a **Final Rejection or Notice of Allowance**, and the requisite Certification or fee under Rule 1.17(p), namely **\$180.00**, is included herein; or
- (4) after the mailing date of a **Final Rejection or Notice of Allowance** but before the payment of the **Issue Fee**, and the requisite Certification, petition, and petition fee are included herein.

It is respectfully requested that each of the documents shown on the attached Form(s) 08B be made of record in this application. Copies of these documents (CHECK ONE):

- X which were not previously disclosed are enclosed herewith; or
- have been cited in the parent application, and are thus not being resubmitted herein.

Early examination and allowance of the present application are respectfully solicited.

FEE AUTHORIZATION

Should any fees associated with the submission be required, the Commissioner is authorized to charge the missing fee to our Deposit Account No. 50-0850. Any overpayments should be credited to said Deposit Account.

Respectfully submitted,

Date: May 26, 2004



David S. Resnick (Reg. No. 34,235)
Nixon Peabody LLP
100 Summer Street
Boston, MA 02110
(617) 345-6057

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Application Number	10/767,870
				Filing Date	01/29/2004
				First Named Inventor	Mark Puder
				Art Unit	To be assigned
				Examiner Name	To be assigned
Sheet	1	of	3	Attorney Docket Number	701039-53543

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
		Number – Kind Code ² (if known)			
AA	US-5,760,068		06/02/1998	Talley et al.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is

place a check mark here if English language Translation is
This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file
(and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2
hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the
individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the
Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR
COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria VA 22313-1450.

FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria VA 22313-1450.
If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449PTO				<i>Complete if Known</i>	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Application Number	10/767,870
				Filing Date	01/29/2004
				First Named Inventor	Mark Puder
				Art Unit	To be assigned
				Examiner Name	To be assigned
Sheet	2	of	3	Attorney Docket Number	701039-53543

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published		T ²
	CA	ELLIS, H. ET AL., "Adhesion-related hospital readmissions after abdominal and pelvic surgery: a retrospective cohort study," Lancet, p. 1476, (1999).		
	CB	MENZIES, D. ET AL., "Small bowel obstruction due to postoperative adhesions: treatment patterns and associated costs in 100 hospital admissions," Ann. R. Coll. Surg. Engl., p. 40-46, (2001).		
	CC	SAED, G. M. ET AL., "Cyclooxygenase-2 is expressed in human fibroblasts isolated from intraperitoneal adhesions but not from normal peritoneal tissues," Fertil. Steril., p. 1404, (2003).		
	CD	DIZEREGA, G.S. ET AL., "Peritoneal repair and post-surgical adhesion formation," Human Reproduction Update, p. 547, (2001).		
	CE	RAY, N.F. ET AL., "Abdominal adhesiolysis: inpatient care and expenditures in the United States in 1994," J. Am. Coll. Surg., p. 1, (1998).		
	CF	CHEGINI, N., "The role of growth factors in peritoneal healing: transforming growth factor beta (TGF-beta)," Eur. J. Surg., p. 17, (1997).		
	CG	WICZYK, H.P. ET AL., "Pelvic adhesions contain sex steroid receptors and produce angiogenesis growth factors," Fertil. Steril., p. 511, (1998).		
	CH	ROUT, U.K. ET AL., "Altered expressions of VEGF mRNA splice variants during progression of uterine-peritoneal adhesions in the rat," Am. J. Reprod. Immunol., p. 299, (2000).		
	CI	MONTZ, F. ET AL., "Ability to minimize postoperative intraperitoneal adhesion formation in a murine model," Fertil. Steril., p. 1136, (1994).		
	CK	RODGERS, K. ET AL., "Reduction of adhesion formation with hyaluronic acid after peritoneal surgery in rabbits," Fertil. Steril., p. 553, (1997).		

Examiner Signature		Date Considered
--------------------	--	-----------------

*EXAMINER if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
Sheet	3	of	3	Application Number	10/767,870
				Filing Date	01/29/2004
				First Named Inventor	Mark Puder
				Art Unit	To be assigned
				Examiner Name	To be assigned
				Attorney Docket Number	701039-53543

CL		DIAMOND, N.P. ET AL., "A model for sidewall adhesions in the rabbit: Reduction by an absorbable barrier," <i>Microsurg.</i> , p. 197, (1987).		
CM		PANAY, N. ET AL., "New directions in the prevention of adhesion in laparoscopic surgery," <i>Curr. Opin. Obstet. Gynecol.</i> , p. 379, (1999).		
CN		SOULES, N. ET AL., "The prevention of postoperative pelvic adhesions: an animal study comparing barrier methods with dextran 70," <i>Am. J. Obstet. Gynecol.</i> , p. 829, (1982).		
CO		WISEMAN, D.M. ET AL., "The rates of adhesion development and the effects of crystalloid solution on adhesion development in pelvic surgery," <i>Fertil. Steril.</i> , p. 702, (1998).		
CP		HANEY A.F. ET AL., "A barrier composed of chemically cross-linked hyaluronic acid (Incert) reduces postoperative adhesion formation," <i>Fertil. Steril.</i> , p. 145, (1998).		
CQ		WALLWIENER, D. ET AL., "Adhesion formation of the parietal and visceral peritoneum: an explanation for the controversy on the use of autologous and alloplastic barriers?," <i>Fertil. Steril.</i> , p. 132, (1998).		
CR		RODGERS, K. ET AL., "Evaluation of polyethylene glycol/polylactic acid films in the prevention of adhesions in the rabbit adhesion formation and reformation sidewall models," <i>Fertil. Steril.</i> , p. 403, (1998).		
CS		DIAMOND, M.P., "Reduction of de novo postsurgical adhesions by intraoperative pre-coating with Sepracoat (HAL-C) solution: a prospective, randomized, blinded, placebo-controlled multicentre study. The Sepracoat Adhesion Study Group.," <i>Fertil. Steril.</i> , p. 1067, (1998).		
CT		BOWERS, D. ET AL., "Hyaluronic acid-carbosymethylcellulose film and perianastomotic adhesions in previously irradiated rats," <i>Am. J. Obstet. Gynecol.</i> , p. 1335-1447 (1999).		
CU		Needleman, P. et al, <i>J. Rheumatol.</i> , 24, Suppl 49:6 - 8 (1997)		
CV		Samad, T. A. et al, <i>Nature</i> , 410(6827):471-5 (2001)		

Examiner Signature		Date Considered
--------------------	--	-----------------

*EXAMINER if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.